HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MyD88 inhibitor LM9

reduced vascular inflammatory responses, oxidative stress, and atherosclerosis in mouse model; see source for structure

Also Known As:

LM9 compound

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - MyD88 inhibitor LM9: 2
  - Piperazines: 26
    - MyD88 inhibitor LM9: 2
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - MyD88 inhibitor LM9: 2

Experts

1.	Liang, Guang: 2 articles (08/2020 - 01/2019)
2.	Chen, Gao-Zhi: 1 article (08/2020)
3.	Fu, Li-Li: 1 article (08/2020)
4.	Liu, Qian: 1 article (08/2020)
5.	Lu, Xiao-Yao: 1 article (08/2020)
6.	Sun, Chu-Chu: 1 article (08/2020)
7.	Zhang, Xiu-Hua: 1 article (08/2020)
8.	Zheng, Xu-Yong: 1 article (08/2020)
9.	Chen, Taiwei: 1 article (01/2019)
10.	Hu, Xiang: 1 article (01/2019)

Related Diseases

1.	Obesity 08/01/2020 - "In conclusion, this study demonstrates that MyD88 inhibitor LM9 exerts protective effects against obesity-induced cardiomyopathy, suggesting LM9 to be a promising therapeutic candidate drug for the obesity-related cardiac complications."
2.	Cardiomyopathies (Cardiomyopathy) 08/01/2020 - "In conclusion, this study demonstrates that MyD88 inhibitor LM9 exerts protective effects against obesity-induced cardiomyopathy, suggesting LM9 to be a promising therapeutic candidate drug for the obesity-related cardiac complications."
3.	Atherosclerosis 01/01/2019 - "This study highlights the translational role of MyD88 as a therapeutic target and identifies the MyD88 inhibitor LM9 as a new candidate for the treatment of atherosclerosis." 01/01/2019 - "A novel MyD88 inhibitor LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages."